

[Save your seat at the 2026 Summit. →](#)[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)[Home](#) / [Resources](#) / [Blog](#)

Clinical-Trial Costing 101: Building a Phase-by-Phase Budget Your Board Will Trust



Max Beauroyre

Head of Growth at Abacum

7 min read • Jun 25, 2025 •

Every finance leader in biotech knows the sinking feeling when a clinical trial budget starts to unravel. Clinical trial costing remains one of the most challenging aspects of life science finance

BIOFRONTERA INC., EXHIBIT 2010

IPR2026-00396 1/14

SUN PHARMACEUTICAL INDUSTRIES, INC. v. BIOFRONTERA INC.

Save your seat at the 2026 Summit. →

Platform

Use Cases

Customers

Resources

Interactive Demo

Log in

Book a demo

trial phases, explains the factors driving budget variability, and provides practical strategies for building [financial plans](#) your board and investors will trust.



season with Abacum

Enter your email

Book a Demo

The leading **FP&A platform** that balances flexibility with ease of use

Request a demo ↗

•--• Abacum

What is the True Cost of Clinical Trials?

Clinical trials cost between \$4 million for Phase I to over \$100 million for Phase III, with per-patient costs ranging from \$113,000 to \$136,000. This significant investment breaks down across site costs (30%), patient recruitment (20%), data management (15%), regulatory compliance (10%), and other expenses including manufacturing and overhead (25%).

Many finance teams underestimate clinical trial costs by 30-40%, creating budget crises that threaten trial completion. The clinical trial cost per patient varies dramatically based on therapeutic area, with oncology and rare disease trials commanding premium budgets. Furthermore, [adaptive trial designs](#) cut total clinical trial costs by 15-25% through early futility stopping rules and dynamic sample size adjustments.

- **Cost drivers:** Protocol complexity, geographic distribution, patient population, regulatory requirements

What is the True Cost of ...

Key Factors that Impact ...

Phase-By-Phase Breakd...

How to Manage Unexpe...

How Geography and Th...

Structuring a Board-Rea...

Transforming Cost Plann...



Save your seat at the 2026 Summit. →

Platform

Use Cases

Customers

Resources

Interactive Demo

Log in

Book a demo

✓ Accurate phase-specific benchmarking

✓ Realistic patient recruitment timelines

✓ Flexible contingency planning

✓ Real-time expense tracking

Key Factors that Impact Clinical Trial Costs

Understanding the primary cost drivers helps finance teams build more accurate budgets and [identify potential savings](#).

1. Site management

Site costs typically consume 30% of clinical trial budgets. Fees vary dramatically by location, with North American sites commanding rates 3-4 times higher than emerging markets. These expenses cover site selection, initiation, staff training, and ongoing monitoring to ensure protocol adherence.

2. Participant recruitment

Patient recruitment represents the most unpredictable cost element in clinical trials. The clinical trial cost per patient increases substantially for rare diseases or specialized populations. These

Save your seat at the 2026 Summit. →[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)

Every clinical trial requires regulatory submissions in each jurisdiction where it operates. These costs include ethics committee fees, regulatory filings, and compliance monitoring throughout the study. Regulatory expenses vary by country and therapeutic area, with oncology trials facing more extensive documentation requirements.

4. Data management

Managing trial data has grown increasingly complex as studies collect more endpoints and use advanced technologies. These costs cover electronic data capture systems, data cleaning, monitoring, and statistical analysis. Advanced data requirements like genomic sequencing or wearable device integration significantly increase expenses.

5. Drug or device manufacturing

Producing study materials represents a substantial budget item. These costs include manufacturing investigational drugs, placebos, comparators, and specialized packaging. Expenses rise dramatically with complex formulations, biologics, or specialized delivery devices requiring GMP compliance.

The banner features a dark blue background with a white geometric pattern of overlapping squares. On the left, the text 'New guide' is in a small white box, followed by '10x CFO: Biotech and Pharma' in large white font. Below this is an orange button with 'Download guide' and a right-pointing arrow. On the right, the Abacum logo is in white. Below the logo, there are three overlapping images: a book cover titled '10x CFO: Biotech and Pharma', a document titled 'Structure to', and a screenshot of a software interface showing a 'Financial Analysis' table and a line graph.

Save your seat at the 2026 Summit. →[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)

budgets and set appropriate contingencies.

1. Phase I costs and per-patient breakdown

Phase I trials cost between \$4-5.26 million total, with an average per-patient cost of \$136,783. These first-in-human studies focus on safety in small cohorts of 15-39 participants. The high per-patient costs reflect intensive monitoring, frequent assessments, and specialized clinical pharmacology units.

2. Phase II costs and per-patient breakdown

Phase II trials range from \$7-20 million total, with average per-patient costs of \$129,777. These studies test efficacy in 71-143 patients with the target condition. Costs reflect more complex endpoints, multiple sites, and longer treatment durations than Phase I.

3. Phase III costs and per-patient breakdown

Phase III trials require \$20-100+ million, with average per-patient costs of \$113,030. These pivotal studies enroll 300-479 patients across multiple countries to establish efficacy and safety. While total costs are highest, per-patient costs decrease slightly due to operational efficiencies.

- **Phase I:** Highest per-patient cost, smallest enrollment, safety focus
- **Phase II:** Moderate per-patient cost, expanded enrollment, efficacy testing
- **Phase III:** Largest total budget, broadest enrollment, definitive results

How much does a clinical trial cost per patient? This question depends heavily on the phase, with early-phase trials having higher per-patient costs due to intensive monitoring and smaller patient pools.

Save your seat at the 2026 Summit. →

Platform

Use Cases

Customers

Resources

Interactive Demo

Log in

Book a demo

Clinical trials rarely proceed exactly as planned, with protocol amendments and enrollment challenges frequently disrupting budgets.

1. Scenario planning with rolling forecasts

Building multiple budget scenarios (best, expected, worst case) helps finance teams anticipate potential changes. Rolling **forecasts** enable regular updates as new data emerges throughout the trial. Financial planning software can automate this process, providing leadership with up-to-date financial visibility.

2. Real-time budget tracking

Implementing systems to track expenses against budget in real time helps identify potential overruns early. Monitoring site-level and patient-level costs provides granular insight into spending patterns. Dashboard reporting creates transparency for stakeholders and enables prompt corrective actions.

3. Contingency allocation

Setting appropriate contingency reserves is essential for managing clinical trial budget risk. Industry best practice suggests allocating 10-15% of the total budget as contingency. Higher percentages are recommended for early-phase or complex trials where uncertainties are greatest.

Tip: Phase I trials typically require higher contingencies (15-20%) due to safety unknowns, while Phase III may need 10-15% focused primarily on enrollment variability.

Save your seat at the 2026 Summit. →[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)

North America represents the highest-cost region for clinical trials, with site costs averaging 2-3 times those in emerging markets. European trials face moderate costs but navigate a complex regulatory landscape. Asia-Pacific regions offer lower site costs but may present logistical challenges.

Therapeutic area significantly influences trial complexity and cost of clinical trials. Oncology trials typically cost 30-40% more than average due to complex protocols and recruitment challenges. CNS and rare disease trials also command premium budgets due to specialized assessments.

Region	Typical Site Cost	Regulatory Complexity	Common Areas
North America	High	Moderate	Oncology, CNS
Europe	Moderate	High	Rare diseases
Asia-Pacific	Low	Variable	Infectious diseases

Strategic considerations for multi-region trials include balancing higher costs against regulatory requirements and market access needs. Many sponsors conduct trials in regions where they plan to commercialize to satisfy local regulatory preferences.

Structuring a Board-Ready Clinical Trial Budget

Creating a clinical trial budget that earns board and investor confidence requires transparency, benchmarking, and [scenario planning](#).

Save your seat at the 2026 Summit. →

Platform

Use Cases

Customers

Resources

Interactive Demo

Log in

Book a demo

contextual support for budget estimates. These benchmarks should be clearly presented alongside the proposed budget to demonstrate diligence.

2. Aligning with investor expectations

Addressing common investor concerns proactively strengthens budget presentations. Different investor types have varying priorities – venture capital firms often emphasize milestone achievement, while public investors focus more on [burn rate](#) implications.

- **VC concerns:** Time to next milestone, enrollment speed, site productivity
- **Public market concerns:** Cash runway, burn rate, comparison to industry standards
- **Strategic partner concerns:** Resource allocation, alignment with portfolio strategy

3. Scenario-based reporting

Presenting best-case, expected-case, and worst-case scenarios gives leadership a complete picture of potential outcomes. Each scenario should include key assumptions, timeline implications, and specific triggers that would shift the project from one scenario to another.

Request a Demo: Streamline Your Clinical Trial Budgeting

See how Abacum can help your finance team build more accurate clinical trial budgets with automated scenario planning, real-time tracking, and board-ready reporting. [See Abacum live](#)

Transforming Cost Planning into Strategic Advantage

Save your seat at the 2026 Summit. →[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)

resources throughout the study. Companies gain competitive advantage by anticipating cost drivers rather than reacting to budget crises. This proactive approach enables faster decision-making when challenges arise.

Integrated financial planning platforms connect clinical and financial data for comprehensive analysis. These systems allow finance teams to collaborate more effectively with clinical operations, providing real-time visibility into how operational decisions impact financial outcomes.

Abacum helps finance teams build more accurate, board-ready clinical trial costs with powerful scenario planning capabilities. The platform's collaborative features enable better alignment between finance and clinical teams, ensuring everyone works from the same financial data. This integration helps transform clinical trial costing from a necessary evil into a strategic advantage.

Frequently Asked Questions

+ How do CRO fees impact the total cost of a clinical trial?

Save your seat at the 2026 Summit. →

[Platform](#)[Use Cases](#)[Customers](#)[Resources](#)[Interactive Demo](#)[Log in](#)[Book a demo](#)

How can finance teams better predict clinical trial budget overruns?

+ What financial metrics should be reported to the board during a clinical trial?

+ How do adaptive trial designs affect clinical trial costing?

Save your seat at the 2026 Summit. →

Platform

Use Cases


Customers

Resources

Interactive Demo

Log in

Book a demo



**Trenches for Scaling Companies
in 2026**

Your work email

Download

Check out our most viewed content

Save your seat at the 2026 Summit. →

Platform

Use Cases


Customers

Resources

Interactive Demo

Log in

Book a demo




Private Equity in the AI Age

Jan 13, 2026 · Julio Martínez


Abacum partners with Profit& to bring enterprise-grade xP&A to mid-market finance teams

Feb 10, 2026 · TJ Dhadwar



What Is Regulatory Reporting And Why Does It Matter In 2026?

Jan 24, 2026 · Jorge Lluch



Save your seat at the 2026 Summit. →

Platform

Use Cases

Customers

Resources

Interactive Demo

Log in

Book a demo

For all the decisions
you need to make.

Enter your work email

Book a
demo



Product Compare
AI-native FP&A that drives business performance

Use cases

Personas

Company

Discover

Save your seat at the 2026 Summit. →

- Platform
- Use Cases
- Customers
- Resources
- Interactive Demo
- Log in
- Book a demo



ISO 27001 certified

Data

FP&A Tools

Investor Reporting

Referral

Blog



GDPR compliant

Integrations

Modeling Tools

P&L, BS, CF

Contact

Webinars

Security

Guides

Templates

Infographics

Interviews

Newsroom

Glossary

What is FP&A